Roche (OTCMKTS:RHHBY) was downgraded by Societe Generale from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday, The Fly reports.
A number of other equities analysts have also commented on the stock. Zacks Investment Research lowered shares of Roche from a “buy” rating to a “hold” rating in a research report on Friday, January 5th. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Roche in a research report on Friday, December 29th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Roche in a research report on Thursday, December 7th. Berenberg Bank lowered shares of Roche from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Finally, Citigroup lowered shares of Roche from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 18th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $36.50.
Shares of Roche (RHHBY) opened at $31.78 on Monday. Roche has a 1 year low of $28.48 and a 1 year high of $36.82. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.29 and a quick ratio of 0.92.
TRADEMARK VIOLATION WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/15/roche-rhhby-downgraded-by-societe-generale.html.
Roche Company Profile
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.